Stockscreener 앱 받기
26.71
6.12%
1.54
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Have Enliven Therapeutics Insiders Been Selling Stock? - Sahm
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Is Enliven Therapeutics Inc. attractive for institutional investorsQuarterly Market Summary & High Return Trade Opportunity Guides - bollywoodhelpline.com
Moving Averages: Does Enliven Therapeutics Inc stock have upside surprise potential2025 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 48,300 Shares of Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $1.35m in ELVN - Investing.com Canada
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 9,635 Shares - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 91,198 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 41,302 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $241,164.05 in Stock - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares By Investing.com - Investing.com UK
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 8%Here's What Happened - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares - Investing.com India
Enliven Therapeutics Insider Sold Shares Worth $3,476,014, According to a Recent SEC Filing - marketscreener.com
Stocks with rising relative price strength: Enliven Therapeutics - MSN
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Enliven Therapeutics (NASDAQ:ELVN) Trading Up 21.1% – Here’s Why - Defense World
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data - Sahm
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - FinancialContent
Enliven Therapeutics (NASDAQ:ELVN) Trading 21.1% HigherTime to Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $25.64 By Investing.com - Investing.com India
Enliven Therapeutics stock hits 52-week high at $25.64 - Investing.com
Enliven reports positive initial phase 1b data for ELVN-001 in CML - Investing.com Nigeria
Enliven Therapeutics, Inc. (ELVN): Investor Outlook Reveals 78% Potential Upside In Biotech Sector - DirectorsTalk Interviews
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Sahm
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
Why Enliven Therapeutics Inc. stock could benefit from AI revolution2025 Earnings Surprises & Growth Focused Entry Point Reports - ulpravda.ru
What risks investors should watch in Enliven Therapeutics Inc. stockWeekly Earnings Recap & Technical Analysis for Trade Confirmation - ulpravda.ru
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data - Yahoo Finance
How Enliven Therapeutics Inc. stock reacts to oil prices2025 Analyst Calls & Long-Term Growth Stock Strategies - Улправда
Is Enliven Therapeutics Inc. stock attractive for hedge fundsTrade Entry Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Enliven touts drug trial results, adds pharma exec to board - BizWest
Enliven Therapeutics’ Initial Leukemia Drug Data Excite Investors, Shares Surge - Bitget
Will Enliven Therapeutics Inc. stock see insider buyingWeekly Stock Report & AI Forecasted Stock Moves - Улправда
Enliven Stock Soars 51% After Positive CML Trial Results - Nasdaq
How supply chain issues affect Enliven Therapeutics Inc. stock2025 Retail Activity & Free Risk Controlled Daily Trade Plans - Улправда
Shorts Report: How Enliven Therapeutics Inc. stock reacts to oil pricesFed Meeting & Daily Oversold Stock Bounce Ideas - Улправда
Enliven surges on trial data for leukemia drug (ELVN:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
ELVN Stock Shot Up 60% Today – What’s Driving The Rally? - Stocktwits
How resilient is Enliven Therapeutics Inc. stock in market downturns2025 Volatility Report & Daily Entry Point Trade Alerts - Улправда
Enliven Stock Soars On Promising Phase 1b Data In Chronic Myeloid Leukaemia - Nasdaq
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month HighHere's Why - MarketBeat
Enliven reports positive initial phase 1b data for ELVN-001 in CML By Investing.com - Investing.com South Africa
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - PR Newswire
Enliven Appoints Scott Garland to Board, Focuses on ELVN-001 Commercialization - Intellectia AI
Enliven Therapeutics continues to prepare for phase 3 trial initiation in 2026 - marketscreener.com
Scott Garland joins Enliven Therapeutics board as company prepares for CML trial - Investing.com Nigeria
Scott Garland joins Enliven Therapeutics board as company prepares for CML trial By Investing.com - Investing.com South Africa
Enliven Therapeutics Announces Board Changes - TradingView — Track All Markets
Veteran cancer-drug leader joins company pushing new CML drug to Phase 3 - Stock Titan
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - Sahm
4.73%
0.92%
자본화:
|
볼륨(24시간):